The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Myeloma at ASH 2020: what to expect?
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA shares key multiple myeloma updates that will be presented at ASH 2020. This includes exciting data on off-the-shelf bispecific T-cell engagers, as well new targets for cellular therapy and updates of large trials such as the Phase III APOLLO study (NCT03180736) evaluating daratumumab and pomalidomide in relapsed/refractory multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
